Detailed Narrative
Recurring Revenue Momentum
Ingersoll Rand achieved significant progress in its recurring revenue initiative, surpassing $450 million in 2025. The company has also built a substantial backlog of approximately $1.1 billion in future revenue from existing contracts, demonstrating strong traction towards its long-term targets. This growth is attributed to expanding into new regions and integrating recurring revenue models across various technologies.
Strategic M&A and Pipeline
The company's disciplined M&A strategy continues to be a key growth driver. In 2025, Ingersoll Rand invested $525 million across 16 transactions, which collectively added approximately $275 million in annualized inorganic revenue at an average pre-synergy multiple of 9x. Heading into 2026, the acquisition pipeline remains robust, with 9 additional transactions currently under Letter of Intent (LOI), including potential larger deals up to $1 billion, though the current pipeline is primarily bolt-on in nature. The first acquisition of 2026, Scinomix, enhances the Life Science strategy.
End Market and Economic Outlook
Ingersoll Rand's portfolio continues to show resiliency, with 40% of revenue derived from stable aftermarket services. Life Sciences is improving sequentially, driven by pharma/biopharma production and medical device opportunities, particularly in China. The general industrial sector has seen increased stability in the latter half of 2025, with cautious optimism for 2026. The long-cycle project funnel remains healthy, though decision-making elongation persists. The company notes the recent uptick in the U.S. PMI as a positive indicator but remains prudent, not baking a significant market recovery into its guidance.
China Market Performance
Despite a challenging market, Ingersoll Rand's team in China has delivered positive organic order growth for three consecutive quarters. This performance is largely attributed to self-help initiatives, including the launch of new localized products and technologies. The strategy involves taking technologies acquired in other regions, localizing them for the Chinese market, and offering differentiated solutions to customers, such as advanced aeration technology for wastewater applications.
Capital Deployment and Balance Sheet Strength
In 2025, Ingersoll Rand demonstrated strong capital deployment, investing $525 million in M&A, executing $1 billion in share repurchases, and distributing $32 million in dividends. The company maintains a robust balance sheet with $3.8 billion in total liquidity and leverage well under 2x, reinforcing its ability to pursue high-return opportunities while maintaining financial flexibility. The 2026 guidance reflects the annualization of prior capital actions and a consistent approach to capital allocation.
Operational Efficiency and Cost Management
The company's 2026 guidance incorporates requisite productivity and cost actions to offset headwinds like tariff impact🌐s and commercial investments. Proactive restructuring actions taken in H2 2025 are expected to yield savings in 2026. Normal course productivity, including direct material and I2V, will follow revenue phasing📎, with a greater impact in the second half. Targeted pricing actions will also be implemented throughout the year to materialize in the revenue base, particularly in H2.